Resmed (RSMDF) Cash from Restructuring (2023)

Resmed (RSMDF) reported Cash from Restructuring of $9.2 million for Q2 2023.

Resmed (RSMDF) Cash from Restructuring (2023) Analysis & Trends

Resmed has reported Cash from Restructuring for 1 years, with the latest figure at $9.2 million in Q2 2023.

For the quarter ending Q2 2023, Cash from Restructuring changed N/A year-over-year to $9.2 million; the trailing twelve-month figure through Mar 2025 stood at $9.2 million (changed N/A YoY), and the FY2024 full-year result was $33.2 million, up 262.2% from the prior year.
Cash from Restructuring for Q2 2023 stood at $9.2 million.
The five-year high for Cash from Restructuring was $9.2 million in Q2 2023, with the low at $9.2 million in Q2 2023.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Intuitive Surgical	148.09 Bn	143.69 Bn	1.83 Bn
2	Becton Dickinson	41.00 Bn	39.99 Bn	2.15 Bn
3	Medline	30.38 Bn	36.22 Bn	1.84 Bn
4	Resmed	28.22 Bn	26.56 Bn	890.98 Mn
5	West Pharmaceutical Services	23.72 Bn	23.19 Bn	296.40 Mn
6	Solventum	13.33 Bn	13.33 Bn	1.10 Bn
7	Cooper Companies	13.12 Bn	12.99 Bn	735.40 Mn
8	Align Technology	12.86 Bn	11.80 Bn	736.59 Mn
9	Baxter International	10.51 Bn	8.47 Bn	891.00 Mn
10	Resmed	-	-	890.98 Mn

Historic Data

Download Data

Date	Value
Jun 30, 2023	9.18 Mn